This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Leonetti, C. Articles by Biroccio, A. Search for Related Content PubMed PubMed Citation Articles by Leonetti, C. Articles by Biroccio, A.

G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors

Authors' Affiliations: ¹ Experimental Chemotherapy Laboratory and ² Department of Pathology, Regina Elena Cancer Institute; ³ Experimental Medicine and Pathology Department II Faculty, S. Andrea, Rome, Italy; ⁴ Department of Oncology, Pharmacological Research Institute "Mario Negri," Milan, Italy; ⁵ Center for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom; and ⁶ Laboratoire de Biologie Moléculaire de la Cellule, CNRS UMR5239, IFR128, Ecole Normale Supérieure de Lyon, Faculté de Médecine Lyon-Sud, Pierre Benite, France

Requests for reprints: Annamaria Biroccio, Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Roma, Italy. Phone: 39-6-52662569; Fax: 39-6-52662592; E-mail: biroccio{at}ifo.it.

Purpose: The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity, offering an original strategy to design and develop new antitumor agents. The pentacyclic acridinium salt RHPS4 is one of the most effective and selective G4 ligands able to rapidly disrupt telomere architecture, resulting in apoptosis of cancer cells. Here, we studied the therapeutic index of RHPS4 and its integration with chemotherapeutics in preclinical model of solid tumors.

Experimental Design: The antitumoral activity of RHPS4 was evaluated on human xenografts of different histotypes and compared with that of standard antineoplastic agents. Moreover, the effect of RHPS4/chemotherapeutics combinations on cell survival was studied and the most favorable combination was evaluated on tumor-bearing mice.

Results: RHPS4 was active in vivo as single agent and showed a high therapeutic efficacy when compared with conventional drugs. Moreover, RHPS4 had antitumoral activity in human melanoma xenografts inherently resistant to chemotherapy and exhibited antimetastatic activity. RHPS4 also showed a strong synergistic interaction with camptothecins and this effect was strictly dependent on the drug sequence employed. Treatment of mice with irinotecan followed by RHPS4 was able to inhibit and delay tumor growth and to increase mice survival.

Conclusions: Our data show that RHPS4 has a good pharmacodynamic profile and in combination therapy produces a strong antitumoral activity, identifying this drug as promising agent for clinical development.